pg. 1
2025 ACRP CCRC EXAM PREP 300 QUESTIONS
AND CORRECT DETAILED ANSWERS (100%
CORRECT ANSWERS) ACRP CCRC EXAM
PRACTICE QS AND AS (NEWEST!)
True or False? If the investigator is a non-physician, the investor should make adequate provision for an necessary medical care. - ANSWER-True
What are three true statements with respect to protecting the rights, safety, and welfare of study subjects? - ANSWER-- Providing subjects with method of communication with the investigator or qualified designee for questions or concerns
- Adhering to the protocol so that study subjects aren't exposed to unreasonable
- Providing reasonable access to needed medical care
risk
True or False? Protecting the rights, safety, and well-being of clinical trial subjects is the most important element of investigator responsibility. - ANSWER-True
True or False? Within the US, clinical investigations of drugs and biological products must be conducted in accordance with 21 CFR part 312. - ANSWER- True
What areas are applicable to assess the adequacy of supervision by an investigator?
- ANSWER-- Whether individuals who were delegated tasks were qualified to
- Whether study staff received adequate training on how to conduct the delegated
reform such tasks
tasks 1 / 4
pg. 2
- Whether there was adequate supervision and involvement in the ongoing conduct
of the study
What are expectations in relation to the qualifications of an investigator? - ANSWER-- Be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial.
- Be thoroughly familiar with appropriate use of IP
- Permit for monitoring and auditing by the sponsor and inspection by the
appropriate regulatory authorities
What are expected or possible consequences of over-estimation of recruitment potential? - ANSWER-- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
What should be the first consideration when conducting a clinical trial? - ANSWER-Subject welfare
When is the investigator allowed to deviate from the protocol? - ANSWER-When there is an immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who world they need to report the deviation and rationale to, if appropriate? - ANSWER-- The Sponsor
- IRB/IEC
- Regulatory Authorities
- / 4
pg. 3 Which conditions should be fulfilled when enrolling a subject into your trial? - ANSWER-- Subject meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you doin't know what the temperature has been over the weekend. You check the current temperature; it's 24C/75F. What should you do? - ANSWER-- Contact the Sponsor, explain what happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects woh already completed their drug intake period. Is this allowed according the E6 Guideline for GCP? - ANSWER-No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What should your course of action be? - ANSWER-You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.
A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). What's your best course of action? - ANSWER- You attempt to retrieve the patients medical history by contacting previous caregivers and you wait for additional information before enrollment. 3 / 4
pg. 4
Who has ultimate trial responsibility for each subject? - ANSWER-The principle investigator.
The concept of pouring the pieces out of the box, trying to put the objects together as quickly as possible, then rebuilding it later is an example of what type of approach? - ANSWER-Retroactive approach
What are three techniques used for process improvement? - ANSWER-- Correction and prevention implementation
- Identify plans for process management
- Conducting a RCA to identify cause of error(s)
What's an example of controlling processes? - ANSWER-Identifying a plan for ongoing management, identify key leaders, and required skills.
What are three applications of adult learning? - ANSWER-- Problem based learning (PBL)
- Clinical problem solving
- Problems require different expertise
What is a tool to identify gap in performance? - ANSWER-Conducting a RCA
True or False? In the US, device trials are to be conducted under CFR part 812. - ANSWER-True
Which countries adhere to ICH GCP guideline to facilitate the mutual acceptance of clinical data? - ANSWER-Japan, Canada, Switzerland, US, EU
- / 4